Zacks Research Weighs in on AstraZeneca PLC’s FY2025 Earnings (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) – Zacks Research raised their FY2025 earnings per share estimates for shares of AstraZeneca in a research note issued to investors on Thursday, September 26th. Zacks Research analyst R. Department now expects that the company will post earnings of $4.54 per share for the year, up from their previous forecast of $4.53. The consensus estimate for AstraZeneca’s current full-year earnings is $4.05 per share. Zacks Research also issued estimates for AstraZeneca’s Q1 2026 earnings at $1.18 EPS and FY2026 earnings at $5.06 EPS.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.01. The firm had revenue of $12.45 billion for the quarter, compared to analyst estimates of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.08 earnings per share.

A number of other research analysts have also weighed in on AZN. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Citigroup upgraded shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. TD Cowen upped their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Finally, Barclays raised AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, AstraZeneca currently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Price Performance

NASDAQ:AZN opened at $77.62 on Monday. AstraZeneca has a 12-month low of $60.47 and a 12-month high of $87.68. The firm has a market capitalization of $240.66 billion, a price-to-earnings ratio of 38.05, a P/E/G ratio of 1.45 and a beta of 0.47. The stock’s 50 day moving average price is $81.68 and its two-hundred day moving average price is $77.10. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69.

AstraZeneca Cuts Dividend

The business also recently announced a Semi-Annual dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were given a dividend of $0.49 per share. The ex-dividend date was Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s payout ratio is 48.04%.

Institutional Investors Weigh In On AstraZeneca

Several institutional investors and hedge funds have recently bought and sold shares of AZN. Centaurus Financial Inc. bought a new stake in AstraZeneca during the second quarter worth $182,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of AstraZeneca by 38,185.0% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 53,599 shares of the company’s stock worth $4,180,000 after buying an additional 53,459 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its stake in AstraZeneca by 122.4% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,728 shares of the company’s stock valued at $135,000 after buying an additional 951 shares in the last quarter. American Trust boosted its stake in AstraZeneca by 27.9% in the second quarter. American Trust now owns 4,387 shares of the company’s stock valued at $342,000 after buying an additional 957 shares in the last quarter. Finally, Heritage Wealth Management Inc. bought a new position in AstraZeneca in the second quarter valued at about $688,000. Institutional investors own 20.35% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.